Dec 14, 2022
Robert Hoffman President, CEO, and Chairman of the Board at Kintara Therapeutics, is developing a drug to treat glioblastoma, the most common and deadliest form of brain tumor. The only drug temozolomide, TMZ, was approved in 1999 and the overall survival rate is very limited. The Kintara drug VAL-083 crosses the blood-brain barrier and is also showing promise for pediatric brain tumors and some ovarian cancers.
Robert explains, "The mechanism of VAL-083 differs from other key chemotherapeutic agents, including TMZ. It induces interstrand cross-links at guanine N07, causing DNA double-strand break and cancer cell death. If you compare that to TMZ, it only induces a single-strand DNA break at N07, and the tumor cells can repair them. That's really an important distinction of our mechanism of action. So, we're really, really excited."
"So, I could imagine once it's approved, physicians would potentially combine it with TMZ, potentially which still may happen. Or Avastin, potentially. So, yes, there is a possibility for that. We're looking at, coincidentally, ovarian cancer with VAL-083 with some PARP inhibitors. So, there are other potential combinations that we're looking at down the road, as well."
"Another underserved area is pediatric brain tumors. We're looking at DIPG, which is a pediatric indication, as well as medulloblastoma"
@Kintara_Thera #Kintara #GBM #Glioblastoma #Cancer #BrainCancer #BrainTumor